IOL Chemicals and Pharmaceuticals net profit rises 43.5% to Rs.107.2 crore in 9M FY24

 07th February, 2024, Ludhiana:

IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the third quarter and nine months ended December 31, 2023.

Consolidated Q3 & 9M FY24 Financial Highlights:                                      

Particulars Q3 FY24 Q3 FY23 % YoY 9M FY24 9M FY23 % YoY
Total Income 528.8 530.1 -0.2% 1651.4 1,646.8 0.3%
EBITDA 52.9 49.7 6.4% 204.0 147.6 38.2%
EBITDA Margin (%) 10.0% 9.4% 60 bps 12.3% 8.9% 340 bps
PAT 23.2 24.2 -4.1% 107.2 74.7 43.5%
PAT Margin (%) 4.4% 4.6% -20 bps 6.5% 4.5% 200 bps

  Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “Despite sectoral headwinds, the Company has shown resilience in its financial performance during nine months period. The company’s EBITDA margin has improved led by declining input cost. We recently received CEP certificate approval for Losartan Potassium by EDQM providing us an opportunity to further expand our exports into the regulated markets. We are continuously focusing on improving operational efficiencies further through backward integration.”